Effect of bortezomib on human neuroblastoma: analysis of molecular mechanisms involved in cytotoxicity

BACKGROUND: Bortezomib, a specific and selective inhibitor of the 26S proteasome with antitumor activity against a wide range of malignancies, has been approved for the treatment of relapsed or refractory multiple myeloma and other cancers. Recently, bortezomib has been identified as an effective in...

Descripción completa

Detalles Bibliográficos
Autores principales: Combaret, Valérie, Boyault, Sandrine, Iacono, Isabelle, Brejon, Stéphanie, Rousseau, Raphaël, Puisieux, Alain
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2442611/
https://www.ncbi.nlm.nih.gov/pubmed/18534018
http://dx.doi.org/10.1186/1476-4598-7-50

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2442611/
https://www.ncbi.nlm.nih.gov/pubmed/18534018
http://dx.doi.org/10.1186/1476-4598-7-50

Ejemplares similares